Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

Pharmacogenomics studies presented at the American Association for Cancer Research's annual meeting in Denver, Colo.

Though Genomic Health's Oncotype Dx colon cancer assay met its primary endpoint in a clinical study, it did not meet a secondary endpoint.

The assay, based on the Oncotype DX platform, met the primary endpoint for determining the likelihood of post-operative disease recurrence in patients with stage II colon cancer, but did not meet the endpoint for the ability to predict benefit from post-operative 5-fluorouracil/leucovorin treatment.

Citing the FDA's handling of KRAS testing for anti-EGFR monoclonal antibodies, the report asserts that in the near term complex genetic tests such as Oncotype DX should be "performed through CLIA labs, and not held up by slow regulatory processes."

Snippets: Apr 1, 2009

Premium

Epigenomics, Response Genetics, Exact Sciences

A group of researchers from Israel and the US report that they have characterized chromosomal abnormalities in different colorectal cancer stages and identified alterations associated with poor outcomes.

The company said that developing the test would be its priority in 2009, putting it on a somewhat accelerated development schedule. Rosetta had originally said the test might not be available until 2010.

New Releases: Mar 25, 2009

Premium

DxS' TheraScreen KRAS Mutation Kit

DxS get EU approval to sell its TheraScreen K-RAS Mutation Kit for use on Roche's LightCycler instrument and licensed rights to related software.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.